Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ABIONYX Pharma

DB:609
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
609
DB
€23M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The last earnings update was 213 days ago. More info.


Add to Portfolio Compare Print
  • ABIONYX Pharma has significant price volatility in the past 3 months.
609 Share Price and Events
7 Day Returns
107.5%
DB:609
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
182.1%
DB:609
-13.2%
DE Biotechs
-20.9%
DE Market
609 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ABIONYX Pharma (609) 107.5% 46.9% 150.9% 182.1% -48.6% -90.2%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 609 outperformed the Biotechs industry which returned -13.2% over the past year.
  • 609 outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
609
Industry
5yr Volatility vs Market

609 Value

 Is ABIONYX Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ABIONYX Pharma. This is due to cash flow or dividend data being unavailable. The share price is €1.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ABIONYX Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ABIONYX Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:609 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in EUR €0.00
ENXTPA:ABNX Share Price ** ENXTPA (2020-04-03) in EUR €1.04
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ABIONYX Pharma.

DB:609 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ABNX Share Price ÷ EPS (both in EUR)

= 1.04 ÷ 0.00

20000x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIONYX Pharma is overvalued based on earnings compared to the Europe Biotechs industry average.
  • ABIONYX Pharma is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does ABIONYX Pharma's expected growth come at a high price?
Raw Data
DB:609 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 20000x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-194.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

DB:609 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 20000x ÷ -194.5%

-102.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIONYX Pharma earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ABIONYX Pharma's assets?
Raw Data
DB:609 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in EUR €0.40
ENXTPA:ABNX Share Price * ENXTPA (2020-04-03) in EUR €1.04
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:609 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ABNX Share Price ÷ Book Value per Share (both in EUR)

= 1.04 ÷ 0.40

2.61x

* Primary Listing of ABIONYX Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ABIONYX Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ABIONYX Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ABIONYX Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

609 Future Performance

 How is ABIONYX Pharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-194.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ABIONYX Pharma expected to grow at an attractive rate?
  • ABIONYX Pharma's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of -0.4%.
Growth vs Market Checks
  • ABIONYX Pharma's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • ABIONYX Pharma's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:609 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:609 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -194.5%
DB:609 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -133.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:609 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:609 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 0 -7 -7 2
2020-04-06
2019-12-31 0 -1 -1 2
DB:609 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -6 0
2019-03-31 0 -6 -3
2018-12-31 0 -6 -6
2018-09-30 0 -6 -7
2018-06-30 -7 -8
2018-03-31 -8 -6
2017-12-31 -9 -5
2017-09-30 -11 -8
2017-06-30 -13 -11
2017-03-31 -16 -18
2016-12-31 -19 -25
2016-09-30 -19 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ABIONYX Pharma's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • ABIONYX Pharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:609 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from ABIONYX Pharma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:609 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.34 -0.34 -0.35 2.00
2020-04-06
2019-12-31 -0.19 -0.03 -0.35 2.00
DB:609 Past Financials Data
Date (Data in EUR Millions) EPS *
2019-06-30 0.00
2019-03-31 -0.17
2018-12-31 -0.34
2018-09-30 -0.38
2018-06-30 -0.42
2018-03-31 -0.35
2017-12-31 -0.27
2017-09-30 -0.44
2017-06-30 -0.60
2017-03-31 -0.99
2016-12-31 -1.39
2016-09-30 -1.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ABIONYX Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ABIONYX Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ABIONYX Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

609 Past Performance

  How has ABIONYX Pharma performed over the past 5 years?

  • ABIONYX Pharma's last earnings update was 213 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ABIONYX Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ABIONYX Pharma has delivered over 20% year on year earnings growth in the past 5 years.
  • ABIONYX Pharma has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • ABIONYX Pharma has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
ABIONYX Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ABIONYX Pharma Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:609 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.17 0.00 2.02 2.39
2019-03-31 0.17 -3.15 2.12 3.06
2018-12-31 0.17 -6.31 2.21 3.73
2018-09-30 0.09 -6.99 2.26 4.08
2018-06-30 -7.68 2.30 4.44
2018-03-31 -6.33 2.02 4.67
2017-12-31 -4.98 1.74 4.90
2017-09-30 -7.95 2.85 6.91
2017-06-30 -10.92 3.96 8.92
2017-03-31 -17.89 5.50 12.96
2016-12-31 -24.87 7.03 17.00
2016-09-30 -24.55 6.35 17.27
2016-06-30 -24.24 5.68 17.54
2016-03-31 -20.44 4.30 15.05
2015-12-31 -16.64 2.91 12.56
2015-09-30 -13.32 2.90 9.43
2015-06-30 -10.01 2.88 6.29
2015-03-31 -8.28 2.92 4.69
2014-12-31 -6.56 2.97 3.10
2013-12-31 -7.74 2.87 6.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • ABIONYX Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • It is difficult to establish if ABIONYX Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ABIONYX Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ABIONYX Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ABIONYX Pharma has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

609 Health

 How is ABIONYX Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ABIONYX Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ABIONYX Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ABIONYX Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ABIONYX Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 9.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ABIONYX Pharma Company Filings, last reported 9 months ago.

DB:609 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 7.66 1.13 9.62
2019-03-31 7.66 1.13 9.62
2018-12-31 3.84 5.50 11.46
2018-09-30 3.84 5.50 11.46
2018-06-30 5.49 6.69 13.51
2018-03-31 5.49 6.69 13.51
2017-12-31 8.89 6.22 16.27
2017-09-30 8.89 6.22 16.27
2017-06-30 13.22 5.67 20.34
2017-03-31 13.22 5.67 20.34
2016-12-31 14.61 7.06 24.68
2016-09-30 14.61 7.06 24.68
2016-06-30 22.36 6.58 32.87
2016-03-31 22.36 6.58 32.87
2015-12-31 33.20 6.09 42.95
2015-09-30 33.20 6.09 42.95
2015-06-30 42.21 0.00 50.66
2015-03-31 42.21 0.00 50.66
2014-12-31 0.01 4.99 7.84
2013-12-31 6.16 0.00 11.14
  • ABIONYX Pharma's level of debt (14.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (80.4% vs 14.8% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on ABIONYX Pharma's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess ABIONYX Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ABIONYX Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

609 Dividends

 What is ABIONYX Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ABIONYX Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of ABIONYX Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ABIONYX Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ABIONYX Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:609 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:609 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 2.00
2020-04-06
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ABIONYX Pharma has not reported any payouts.
  • Unable to verify if ABIONYX Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ABIONYX Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ABIONYX Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ABIONYX Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess ABIONYX Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ABIONYX Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ABIONYX Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

609 Management

 What is the CEO of ABIONYX Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cyrille Tupin
COMPENSATION €4,641,579
TENURE AS CEO 0.6 years
CEO Bio

Mr. Cyrille Tupin, CPA is Chief Executive Officer and Director at ABIONYX Pharma SA since September 6, 2019. Mr. Tupin served as the Chief Financial and Administrative Officer at ABIONYX Pharma SA and served as its Deputy Chief Executive Officer from December 18, 2018 to September 6 , 2019. Mr. Tupin served as Vice President of Finance of ABIONYX Pharma SA. Mr. Tupin served as Director of Finance of ABIONYX Pharma SA. Mr. Tupin previously served as an Audit Director of Sygnatures, the largest private audit and consultant company in Toulouse, France. Prior to that, Mr. Tupin spent more than seven years with PricewaterhouseCoopers. Mr. Tupin has worked on a number of high-profile business transactions including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been French Certified Public Accountant since 2002.

CEO Compensation
  • Insufficient data for Cyrille to compare compensation growth.
  • Cyrille's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ABIONYX Pharma management team in years:

3.2
Average Tenure
60
Average Age
  • The tenure for the ABIONYX Pharma management team is about average.
Management Team

Cyrille Tupin

TITLE
CEO & Director
COMPENSATION
€5M
TENURE
0.6 yrs

Jean-Louis Dasseux

TITLE
Co- Founder & Director
COMPENSATION
€401K
AGE
60
TENURE
15.3 yrs

Christian Chavy

TITLE
Chief Executive Officer of Stallergenes & Director
COMPENSATION
€28K
AGE
69
TENURE
1.3 yrs

Emmanuel Fougeroux

TITLE
Chief Accounting Officer

Renée Benghozi

TITLE
Chief Medical Officer
TENURE
5.2 yrs

Gavin Sy

TITLE
Chief Production Officer

Constance Keyserling

TITLE
Senior Vice President of Clinical Development
AGE
58
Board of Directors Tenure

Average tenure and age of the ABIONYX Pharma board of directors in years:

3.9
Average Tenure
61
Average Age
  • The tenure for the ABIONYX Pharma board of directors is about average.
Board of Directors

Emmanuel Huynh

TITLE
Chairman of the Board
TENURE
0.6 yrs

Cyrille Tupin

TITLE
CEO & Director
COMPENSATION
€5M
TENURE
0.6 yrs

Jean-Louis Dasseux

TITLE
Co- Founder & Director
COMPENSATION
€401K
AGE
60

Christian Chavy

TITLE
Chief Executive Officer of Stallergenes & Director
COMPENSATION
€28K
AGE
69
TENURE
5.2 yrs

Michael Davidson

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
€23K
AGE
62

Karen Noël

TITLE
Director
COMPENSATION
€13K
TENURE
2.8 yrs

Olivier Martinez

TITLE
Director
AGE
49
TENURE
5.2 yrs

Laura Coruzzi

TITLE
Independent Director
COMPENSATION
€20K
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess ABIONYX Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ABIONYX Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

609 News

Simply Wall St News

609 Company Info

Description

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Details
Name: ABIONYX Pharma SA
609
Exchange: DB
Founded: 2005
€22,736,285
21,861,813
Website: http://abionyx.com
Address: ABIONYX Pharma SA
33-43 av. Georges Pompidou – Bât. D2,
Labege,
Midi-Pyrénées, 31130,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ABNX Common Shares Euronext Paris FR EUR 30. Mar 2015
OTCPK THRP.F Common Shares Pink Sheets LLC US USD 30. Mar 2015
DB 609 Common Shares Deutsche Boerse AG DE EUR 30. Mar 2015
BST 609 Common Shares Boerse-Stuttgart DE EUR 30. Mar 2015
LSE 0RAG Common Shares London Stock Exchange GB EUR 30. Mar 2015
Number of employees
Current staff
Staff numbers
5
ABIONYX Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:48
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/10
Last earnings filing: 2019/09/06
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.